Published in Vaccine Weekly, December 28th, 1998
The current hepatitis B virus (HBV) vaccine is based on the HBV surface antigen (HBsAg). However, not only does it fail to elicit protective immunity in 5 to 10 percent of vaccinees, it also fails to protect against HBV mutants bearing HBsAg variants. Thus a vaccine based on multiple determinants should be more effective - and it would work even better if it elicited HBV-specific cellular immunity as well as anti-HBV humoral responses.
To this end, Mengji Lu of the University of Essen, Germany, and colleagues developed two HBV DNA...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly